However, the other HDAC inhibitors approved by the FDA (U.S. Food and Drug Administration) for lymphoma or myeloma therapy (vorinostat, belinostat, and panobinostat) are synthetic compounds with hydroxamic acid zinc binding groups (ZBG). Here, HDAC9 is linked to lymphoma.